Clinical Trials Sponsored by Synta Pharmaceuticals Corp.

Total 73 results

Synta Pharmaceuticals Corp.

Completed

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Solid Tumors

United States
Synta Pharmaceuticals Corp.

Completed

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Melanoma

United States
Synta Pharmaceuticals Corp.

Completed

A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States
Synta Pharmaceuticals Corp.

Completed

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

Prostate Cancer

United States
Synta Pharmaceuticals Corp.

Completed

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada
Synta Pharmaceuticals Corp.

Completed

A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas

Soft Tissue Sarcoma

United States, Canada
Synta Pharmaceuticals Corp.

Completed

STA-5326 in Crohn's Disease Patients

Crohn's Disease

United States
Synta Pharmaceuticals Corp.

Completed

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor

United States
Synta Pharmaceuticals Corp.

Completed

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer (Enchant)

Breast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment

Spain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
Synta Pharmaceuticals Corp.

Completed

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

Solid Tumor Malignancies

United States
Synta Pharmaceuticals Corp.

Completed

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | AML | CML | ALL | Blast-phase Chronic Myelogenous Leukemia

United States
Synta Pharmaceuticals Corp.

Unknown

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Solid Tumors

United States
Synta Pharmaceuticals Corp.

Completed

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Myeloproliferative Disorders | AML | MDS | CML

United States
Synta Pharmaceuticals Corp.

Completed

STA-4783 and Paclitaxel for Treatment of Solid Tumors

Neoplasms

United States
Synta Pharmaceuticals Corp.

Completed

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
Synta Pharmaceuticals Corp.

Terminated

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-Small-Cell Lung Adenocarcinoma

United States, France, Spain, Netherlands, Czech Republic, Serbia, Romania, Germany, Belgium, Italy, Hungary, United Kingdom, Canada, Poland, Bosnia and Herzegovina, Austria, Slovenia, Croatia, Russian Federation, Ukraine
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
Synta Pharmaceuticals Corp.

Completed

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) (CHIARA)

Non Small Cell Lung Cancer

United States, Canada
Synta Pharmaceuticals Corp.

Completed

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States
Synta Pharmaceuticals Corp.

Terminated

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Melanoma

United States, Spain, Canada, Australia, Germany, Puerto Rico, Romania, United Kingdom
Synta Pharmaceuticals Corp.

Completed

A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes

Active, Moderate to Severe Rheumatoid Arthritis

Netherlands
Synta Pharmaceuticals Corp.

Unknown

Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

Canada
Synta Pharmaceuticals Corp.

Suspended

A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors

Metastatic Solid Tumors

United States
Synta Pharmaceuticals Corp.

Completed

STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

Lymphoma | Leukemia | Hematological Malignancies | Metastatic or Unresectable Solid Tumors

United States
Emory University
Synta Pharmaceuticals Corp.

Terminated

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditions

United States
Emory University
Synta Pharmaceuticals Corp.

Completed

Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer

Rectal Cancer

United States
Georgetown University
Synta Pharmaceuticals Corp.

Terminated

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Cancer | Small Cell Lung Cancer

United States
Dana-Farber Cancer Institute
Synta Pharmaceuticals Corp.

Terminated

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Synta Pharmaceuticals Corp.

Completed

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Synta Pharmaceuticals Corp.

Completed

Clinical and Translational Study of STA-9090

Rectal Cancer | Colon Cancer

United States
Emory University
Synta Pharmaceuticals Corp.; Multiple Myeloma Research Consortium

Completed

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
RXi Pharmaceuticals, Corp.

Unknown

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Age-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal Fibrosis

United States
RXi Pharmaceuticals, Corp.

Unknown

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

Hypertrophic Scar

United States, Honduras
RXi Pharmaceuticals, Corp.

Completed

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

Hypertrophic Scar

United States, Honduras
RXi Pharmaceuticals, Corp.

Completed

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

Keloid

United States, Dominican Republic
RXi Pharmaceuticals, Corp.

Completed

Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109

Cicatrix | Scar Prevention

United States
RXi Pharmaceuticals, Corp.

Unknown

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

Plantar Warts | Common Warts | HPV (Human Papillomavirus) | Periungual Warts

United States
RXi Pharmaceuticals, Corp.

Completed

Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109

Cicatrix | Scar Prevention
Eagle Vision Pharmaceutical Corp.

Completed

Safety and Efficacy of SeeMore (TM) in Heart Patients

Myocardial Infarction
Sarcoma Alliance for Research through Collaboration
United States Department of Defense; Synta Pharmaceuticals Corp.

Completed

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Sarcoma | Malignant Peripheral Nerve Sheath Tumors (MPNST)

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...

Completed

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Esophagogastric Cancer

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...

Completed

STA-9090 in Patients With Advanced Hepatocellular Cancer

Hepatocellular Carcinoma

United States
Synta Pharmaceuticals Corp.
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

Crohn's Disease

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Synta Pharmaceuticals Corp.; New York University...

Completed

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Yonsei University
Chong Kun Dang Pharmaceutical Corp.

Unknown

Assessment of Change in Atherosclerotic Plaque by Serial CCTA (ACROSS)

Coronary Artery Disease | Coronary Arteriosclerosis | Hydroxymethylglutaryl-CoA Reductase Inhibitors

Korea, Republic of
Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd

Enrolling by invitation

To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer

Gastrointestinal Cancer

China
University of California, San Diego
Raptor Pharmaceuticals Corp.

Completed

Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™

Cystinosis | Nephropathic Cystinosis

United States
Stony Brook University
Endo Pharmaceuticals; Biospecifics Technologies Corp.

Completed

Collagenase in the Treatment of Dupuytrens Disease

Dupuytren's Disease

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Completed

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Ocular Melanoma

United States
David M. Jackman, MD
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...

Completed

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States

Clinical Trials Sponsored by Synta Pharmaceuticals Corp.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations